Intraoperative Blood Pressure Measurement Modalities Are Separate and Not Equal
To the Editor:
We read with great interest the recent publication by Wax et al.. 1 The authors argue that because noninvasively detected blood pressure tends to be higher than that measured invasively in hypotensive patients and lower in hypertensive patients, some patients monitored with invasive arterial lines alone may undergo potentially harmful vasoactive and transfusion therapy if hemodynamic instability is not confirmed with noninvasive means. However, in the absence of outcome studies following these cohorts (patients whose treatment was guided by invasive arterial lines alone vs. those in whom such therapy was withheld based on noninvasive readings), one cannot make the authors' claim: it remains entirely possible that the reliance on confirmatory noninvasive reading leads to potentially harmful undertreatment.
In reality, invasive and noninvasive modalities of blood pressure measurement use vastly different physical phenomena. Whereas an invasive line displays a direct, electronically processed, beat-to-beat intravascular pressure waveform, the noninvasive tool used in the study is an indirect oscillometric device. Oscillometric parameters are derived, not measured, from the superimposition of a pulse oscillogram envelope on a cuff pressure curve, with mean blood pressure determined at the point of maximal oscillations. Proprietary software algorithms, specific to individual manufacturers, are utilized in analyzing the slopes of scillograms to derive systolic and diastolic readings. These manufacturer-specific algorithms are generally not standardized for measurement accuracy, 2, 3 and, in addition to numerous other technical (i.e., the rate of cuff "bleed") and clinical (i.e., size and location of the cuff not recorded in the authors' database, and elastic properties of the vasculature) variables, affect the reliability of indirect oscillographic determinations. Therefore, in critically ill patients, noninvasive blood pressure measurements are generally considered unreliable. 4, 5 We applaud Wax et al. for their confirmation of a significant discrepancy between the direct and indirect modalities of blood pressure measurement, but would caution against withholding therapy based on nonuniformly standardized, and possibly inaccurate, confirmatory data. In Reply:
We appreciate the concerns raised in Gologorsky et al.'s correspondence regarding our report of intraoperative radial invasive (ABP) versus brachial noninvasive (NIBP) blood pressure monitoring. 1 We acknowledged in our discussion that there could be debate about which is the "real" pressure we should base clinical decisions upon and presented arguments for both, but offered no recommendation other than to consider both sources of data. As a global test of potential harm, we analyzed some short-term outcomes for those who did and did not have NIBP monitoring and did not find significantly worse outcomes for those who had NIBP monitoring (and its associated fewer transfusions or vasopressor uses). We agree that it would be valuable to do further study of the risks/benefits of withholding therapy, but there are already substantial data to suggest that transfusion, for whatever reason, may lead to worse outcomes and that avoidance of transfusion may be a safer alternative in the perioperative setting. 2 We also recognize that NIPB and ABP are completely different technologies. Our data, however, not only compared invasive versus noninvasive modalities, but radial versus brachial sites as well. Brachial pressure may be closer to central pressure than radial pressure because radial pressure may sometimes reflect loss of vascular tone in the hand rather than indicating central hypotension. In order to test for this phenomenon in the setting of low ABP and higher NIBP, a wrist compression test has been suggested that will reportedly increase radial pressure closer to central pressure without overshooting. 3 Had we used axillary ABP data, our results may have been very different, because our impression is that differences between brachial NIBP and axillary ABP are less than those found in our study. Finally, our patients were in a perioperative setting and not necessarily critically ill, intensive care unit patients in whom much of the data raising concerns about NIBP monitoring have been focused on. Indeed, the authors confirmed previous findings that objective acceleromyographic neuromuscular monitoring may improve perioperative neuromuscular management. 2 In the current study this improved perioperative management led to a better spontaneous recovery at the time of neostigmine administration: 61 of 76 patients in the acceleromyographic group compared with 41 of 74 patients in the control group had a train-of-four (TOF) count of 4 when neostigmine was given: P ϭ 0.014. However, it is well known that the degree of spontaneous recovery at the time of neostigmine administration may have a major effect on neostigmine's efficacy. In this context Kirkegaard et al. 3 reported that 20 min after the administration of neostigmine 70 g/kg Ϫ1 at a TOF count of 4 the incidence of residual paralysis (defined as a TOF ratio less than 0.9) was 25%. This incidence increased to 56% when neostigmine was given at a TOF count of 2 instead of 4 without changing any of the other parameters. 3 Unfortunately, the timing of neostigmine administration was hardly controlled in the trial by Murphy et al. 2 and therefore some points seem quite unclear to us: first, according to the Methods section neostigmine should be given when a TOF count of at least 3 was present. In the Results section, however, the TOF count at the time of neostigmine administration ranged from a TOFcount between 0 and 4. Second, and as mentioned previously, the number of patients who had a TOF count of 4 at this time was increased by 30% in the acceleromyographic group versus control. Murphy et al. found a significant difference in repeat doses of rocuro-nium between the two groups during the last 45 min of the surgical procedure, a finding that is supposed to explain the effect in the acceleromyographic group. As stated in the Methods section, participating anesthesiologists were allowed to use "TOF ratio data to guide neuromuscular blocking agents dosing when surgical relaxation was not longer required." The authors are requested to provide some information about the management of neuromuscular blocking agents dosing in the control group during this period. Third, most patients (102 of 150) had 4 TOF responses at the moment of neostigmine administration. It is not obvious whether these patients all had a simple TOF count of 4 (4 responses present with the first response less than 20%; the TOF-Watch SX [Bluestar Enterprises, Omaha, NE] display shows the TOF count) or whether recovery was even more advanced in some patients (still 4 responses present but the first response more than 20%; the TOF-Watch SX calculates and shows the TOF ratio). Further, it should be reported if and how this distinction was made in the control group. Finally, it would be interesting to know if all patients received a standard dose of 50 g/kg Ϫ1 neostigmine, even in case of a deeper residual block with less than three twitch responses. Some information about the real doses of neostigmine that have been used could be helpful in this context.
Based on the information provided, we must conclude that the difference in symptoms of muscle weakness and improved quality of recovery observed in this study could simply be the consequence of the dose or the timing of the administration of neostigmine rather than the direct consequences of intraoperative acceleromyographic monitoring as supposed by Murphy et al.
We suggest that the authors should complete the missing information and report the incidence of residual blockade and associated unpleasant symptoms of muscle weakness separately according to the patients' individual TOF count at the time of neostigmine administration to clarify this key issue. In our opinion, these data are essential for the reader to allow a correct interpretation of the results and, thus, to improve patient's safety. Moreover, it would be very instructive to see whether there were any significant differences in unpleasant symptoms if neostigmine was given at TOF count of 4 independently from the technique of determination (acceleromyographic or conventional qualitative monitoring, respectively), as supposed by Murphy et al. Currently, we are in doubt about this issue.
In addition, the number of included patients reported in the "What This Article Tells Us That Is New" section is probably incorrect and should be 155 instead of 115.
